Medication Monitor



Generic Name (Trade Name—Company)
Notes
June 12, 2019

Eltrombopag

(Promacta—Novartis)
Potential peanut contamination prompts Promacta recall

Norvartis is voluntarily recalling three lots (8H57901589, 9H57900189, and 9H57900289) of eltrombopag 12.5 mg for oral suspension to the consumer level because of a risk of potential peanut flour contamination.

Eltrombopag 12.5 mg for oral suspension is indicated for treatment of chronic immune thrombocytopenia, hepatitis C-associated thrombocytopenia, and severe aplastic anemia in certain adult and pediatric patients who have not received prior immunosuppressive therapy or had an insufficient response to immunosuppressive therapy.

Eltrombopag tablets in 12.5-, 25-, 50-, and 75-mg strengths are not affected by this recall and are not manufactured in the same facility.

Eltrombopag 12.5 mg for oral suspension was distributed nationwide through specialty pharmacies.

To date, Novartis has not received any reports or adverse events for this recall.